About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trialNORTH CHICAGO, Ill., Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing ...

High yields aren't a warning indicator with these three stocks.Should a high dividend yield raise a yellow flag for investors? In some cases, yes. But not always. There are select stocks out there with relatively safe dividends that also happen to have exceptionally high yields for temporary reasons or just because of the nature of the business they operate. The trick is being able to distinguish which ones are traps and which offer opportunities.To help you in your search, three Fool.com contributors have ...

This Dividend King truly wears the crown.Certifications such as the Good Housekeeping Seal help consumers know which products are safe and perform well. Unfortunately, no Good Housekeeping Seal exists for dividend stocks.However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a company must increase its dividend for at least 50 consecutive years. Most income investors will sleep better at night knowing that a stock has such an impressive divid ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.AbbVie currently has an average brokerage recommendation (ABR) of ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.If you're investing in stocks that have long track records for increasing their payouts, odds are, you're buying shares of them because of their stability and the potential for dividend income. But just because a stock is an excellent dividend investment doesn't mean it can't also be a top growth stock to own. Stocks that can balance both dividends and growth can give investors the best of b ...

Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.And when considering dividend-paying stocks, those with a history of boosting their payout are prime considerations, reflecting their commitment to increasingly rewarding shareholders.In addition, consistent dividend hikes reflect the company’s successful nature, opting to share profits with shareholders.And recently, three companies – AbbVie (ABB ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this drugmaker have returned +3.5% over the past month versus the Zacks S&P 500 composite's -0.5% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 4.8% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumors ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35565 AbbVie Inc. (Exact name of registrant as specified in its charter) Delaware 32-0375147 (State or other jurisdiction o ...

The story with AbbVie NYSE: ABBV in 2024 is that it fell off a patent cliff but survived. It survived and continues to thrive because of its strengths in its core immunology portfolio and diversification efforts. While Humira sales continue to flag, falling more than expected in Q3, sales of Rinvoq and Skyrizi are ramping and more than make up the difference. Sales in other segments, including oncology and neurology, also underpin the pharmaceutical company’s growth and are expected to remain strong, if not ...